Risankizumab, guselkumab, and ustekinumab were associated with the lowest risk for progression from psoriasis to psoriatic arthritis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results